Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

First International Summit on Interventional Pharmacoeconomics

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Opening Session Panel Discussion

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Related Videos

Opening Session Panel Discussion

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides

HCC LLM Advice and Treatment Concordance

Can a Genetic Variant Affect the Efficacy of Abiraterone

Breast Cancer Risk May Be Linked to Physical Activity Levels in Adolescence

What Is Causing a Rise in Early-Onset Gastrointestinal Cancers, Including Pancreatic Cancer?